Vistagen Therapeutics, Inc. (VTGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vistagen Therapeutics, Inc. on March 18, 2026, covering the event date of March 17, 2026. The company is incorporated in Nevada and its common stock trades on the Nasdaq Capital Market under the symbol VTGN.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the resignation of Mary Rotunno from the Board of Directors. Her resignation is effective April 1, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of the director's departure.
Key Facts for Investor Verification
- Mary Rotunno resigned from the Board of Directors effective April 1, 2026.
- The resignation was announced on March 17, 2026.
- Shawn K. Singh, President and CEO, signed the report on March 18, 2026.
- No financial results or operational updates are included in this specific filing.